Work

Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?

Year: 2018

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2018.04.032

Authors: J.A. Dottino, H.A. Moss, K.H. Lu, A.A. Secord, L.J. Havrilesky

Institutions: The University of Texas MD Anderson Cancer Center, Duke Medical Center, Duke University, Duke Cancer Institute

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2810748527

FWCI: 0.169

Cites:

Cited by: 2

Related to: 10